MX9708854A - Terapia de genes para regulacion de celulas efectoras. - Google Patents

Terapia de genes para regulacion de celulas efectoras.

Info

Publication number
MX9708854A
MX9708854A MX9708854A MX9708854A MX9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A
Authority
MX
Mexico
Prior art keywords
nucleic acid
encoding nucleic
present
acid molecules
gene therapy
Prior art date
Application number
MX9708854A
Other languages
English (en)
Spanish (es)
Inventor
Steve W Dow
Robyn E Elmslie
Terence A Potter
Original Assignee
Nat Jewish Ct For Immunology A
Respiratory Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/446,918 external-priority patent/US5705151A/en
Application filed by Nat Jewish Ct For Immunology A, Respiratory Medicine filed Critical Nat Jewish Ct For Immunology A
Publication of MX9708854A publication Critical patent/MX9708854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX9708854A 1995-05-18 1997-11-17 Terapia de genes para regulacion de celulas efectoras. MX9708854A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/446,918 US5705151A (en) 1995-05-18 1995-05-18 Gene therapy for T cell regulation
US08/580,806 US5935568A (en) 1995-05-18 1995-12-29 Gene therapy for effector cell regulation

Publications (1)

Publication Number Publication Date
MX9708854A true MX9708854A (es) 1998-08-30

Family

ID=27034800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708854A MX9708854A (es) 1995-05-18 1997-11-17 Terapia de genes para regulacion de celulas efectoras.

Country Status (8)

Country Link
US (1) US5935568A (enExample)
EP (1) EP0850071A4 (enExample)
JP (1) JPH11508762A (enExample)
KR (1) KR19990014875A (enExample)
AU (1) AU704012B2 (enExample)
CA (1) CA2221305A1 (enExample)
MX (1) MX9708854A (enExample)
WO (1) WO1996036366A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075119A (en) 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
BR9815493A (pt) * 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
WO1999036433A2 (en) * 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
AU749625B2 (en) * 1998-01-16 2002-06-27 Johns Hopkins University, The Oral delivery of nucleic acid vaccines by particulate complexes
CA2792479A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
DE69837350T2 (de) * 1998-04-20 2007-11-29 Torrey Pines Institute For Molecular Studies, San Diego Topische immunostimulierung zur induzierung der migration der langerhanszellen
EP1073749B1 (en) * 1998-04-22 2006-01-11 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
EP1089751A4 (en) * 1998-06-23 2001-07-25 Univ Leland Stanford Junior Adjuvant therapy
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
EP1105154B1 (en) * 1998-08-13 2016-06-01 Walter Reed Army Institute of Research Bacterial superantigen vaccines
WO2000020598A1 (en) * 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
AU5178800A (en) * 1999-06-01 2000-12-18 Cornell Research Foundation Inc. Activation of dendritic cells to enhance immunity
US7361329B2 (en) * 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
WO2004044155A2 (en) * 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2005023853A1 (ja) 2003-09-05 2005-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute プロテアーゼ耐性ｓｅｂ改変体およびそれを含むワクチン
CA2863532A1 (en) * 2012-02-08 2013-08-15 Premune Ab Prevention of inflammatory disorders in domestic non-human mammals

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991004272A1 (en) * 1989-09-19 1991-04-04 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
DE69133484T2 (de) * 1990-01-17 2006-05-18 Terman, David S., Pepple Beach Verwendung von Staphylococcus-Enterotoxinen oder verwandte Verbindungen für Krebs-Therapie
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
EP0499003A1 (en) * 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995000178A1 (en) * 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy

Also Published As

Publication number Publication date
EP0850071A4 (en) 2005-05-25
AU704012B2 (en) 1999-04-01
US5935568A (en) 1999-08-10
KR19990014875A (ko) 1999-02-25
EP0850071A1 (en) 1998-07-01
AU5801696A (en) 1996-11-29
JPH11508762A (ja) 1999-08-03
CA2221305A1 (en) 1996-11-21
WO1996036366A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
DE69731540D1 (de) Behandlung von diarrhoe
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69635899D1 (de) Polypeptid, das die differenzierung unterdrueckt
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AU6989094A (en) Compositions and methods for treating cancer and hyperproliferative disorders
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
NO960309L (no) Agonister og antagonister for humaninterleukin-10
IL148152A0 (en) Sequence-specific dna recombination in eukaryotic cells
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
Schluesener et al. Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides
CA2272407A1 (en) Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
WO2000045849A3 (en) Use of cationic lipids to generate anti-tumor immunity
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BR0317132A (pt) Métodos de diagnóstico e tratamento de doença pulmonar intersticial
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
WO2001024764A3 (en) Cell targeting compositions and methods of using the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal